Paul Milan, Ghosh Balaram, Biswas Swati
Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Jawahar Nagar, Medchal, Hyderabad, 500078, Telangana, India.
Drug Deliv Transl Res. 2025 Feb;15(2):621-637. doi: 10.1007/s13346-024-01619-5. Epub 2024 May 16.
Photodynamic Therapy (PDT) is a promising paradigm for treating cancer, especially superficial cancers, including skin and oral cancers. However, the effectiveness of PDT is hindered by the hydrophobicity of photosensitizers. Here, chlorin e6 (Ce6), a hydrophobic photosensitizer, was loaded into pluronic F127 micelles to enhance solubility and improve tumor-specific targeting efficiency. The resulting Ce6@F127 Ms demonstrated a significant increase in solubility and singlet oxygen generation (SOG) efficiency in aqueous media compared to free Ce6. The confocal imaging and fluorescence-activated cell sorting (FACS) analysis confirmed the enhanced internalization rate of Ce6@F127 Ms in murine melanoma cell lines (B16F10) and human oral carcinoma cell lines (FaDu). Upon laser irradiation (666 nm), the cellular phototoxicity of Ce6@F127 Ms against B16F10 and FaDu was approximately three times higher than the free Ce6 treatment. The in vivo therapeutic investigations conducted on a murine model of skin cancer demonstrated the ability of Ce6@F127 Ms, when combined with laser treatment, to penetrate solid tumors effectively, which resulted in a significant reduction in tumor volume compared to free Ce6. Further, the Ce6@F127 Ms demonstrated upregulation of TUNEL-positive cells, downregulation of proliferation markers in tumor tissues, and prevention of lung metastasis with insignificant levels of proliferating cells and collagenase, as validated through immunohistochemistry. Subsequent analysis of serum and blood components affirmed the safety and efficacy of Ce6@F127 Ms in mice. Consequently, the developed Ce6@F127 Ms exhibits significant potential for concurrently treating solid tumors and preventing metastasis. The photodynamic formulation holds great clinical translation potential for treating superficial tumors.
光动力疗法(PDT)是一种很有前景的癌症治疗模式,尤其适用于治疗包括皮肤癌和口腔癌在内的浅表癌症。然而,光动力疗法的有效性受到光敏剂疏水性的阻碍。在此,将疏水性光敏剂二氢卟吩e6(Ce6)负载到普朗尼克F127胶束中,以提高其溶解度并改善肿瘤特异性靶向效率。与游离Ce6相比,所得的Ce6@F127胶束在水性介质中的溶解度和单线态氧生成(SOG)效率显著提高。共聚焦成像和荧光激活细胞分选(FACS)分析证实,Ce6@F127胶束在小鼠黑色素瘤细胞系(B16F10)和人口腔癌细胞系(FaDu)中的内化率有所提高。在激光照射(666 nm)下,Ce6@F127胶束对B16F10和FaDu的细胞光毒性比游离Ce6处理高约三倍。在皮肤癌小鼠模型上进行的体内治疗研究表明,Ce6@F127胶束与激光治疗相结合时,能够有效穿透实体瘤,与游离Ce6相比,肿瘤体积显著减小。此外,通过免疫组织化学验证,Ce6@F127胶束显示TUNEL阳性细胞上调,肿瘤组织中增殖标志物下调,并预防肺转移,增殖细胞和胶原酶水平不显著。随后对血清和血液成分的分析证实了Ce6@F127胶束在小鼠中的安全性和有效性。因此,所开发的Ce6@F127胶束在同时治疗实体瘤和预防转移方面具有显著潜力。这种光动力制剂在治疗浅表肿瘤方面具有巨大的临床转化潜力。